

# **Press Release**

# STADA welcomes Ingo Schachel as Head of Investor Relations

- Investor Relations specialist Ingo Schachel strengthens STADA's senior management team as of 1<sup>st</sup> December
- Ingo Schachel has 20 years of experience in banking, equity research and investor relations
- STADA CEO Peter Goldschmidt: "Ingo's in-depth knowledge of investor relations, equity research and capital markets will be invaluable in further strengthening our trusting relationships with the financial community to support our continued growth journey"

**Bad Vilbel, Germany – 2 December 2024** – STADA has further strengthened its senior management team by welcoming Ingo Schachel as Head of Investor Relations from 1<sup>st</sup> December. Based at the group's headquarters in Bad Vilbel, Germany, he reports directly to Chief Financial Officer Boris Döbler.

Benefitting from more than 20 years of experience in the fields of banking, equity research and investor relations, Schachel was most recently head of investor relations at publicly-listed leader for high-efficiency propulsion and drivetrain technology RENK Group AG.

"Ingo is an excellent addition to our senior management team. His in-depth knowledge of investor relations, equity research and capital markets will be invaluable in further strengthening our trusting relationships with the financial community to support our continued growth journey," commented STADA CEO Peter Goldschmidt.



Schachel started his career in the banking sector at WestLB AG and later at Commerzbank AG, where he held senior positions in equity research for around 15 years. Following a move to BNP Paribas, where he built a new Frankfurt-based research team for the equity franchise, he in September 2023 joined RENK to lead its successful listing on the Frankfurt stock exchange as Head of Investor Relations. Schachel also has experience of public and government relations, having served as a press officer for a member of the German parliament.

#### **About STADA Arzneimittel AG**

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in more than 100 countries. In financial year 2023, STADA achieved group revenues of EUR 3,734.8 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 802.1 million. As of 31 December 2023, STADA employed 11,667 people worldwide.

## Additional information for journalists:

STADA Arzneimittel AG - Media Relations Stadastrasse 2-18 61118 Bad Vilbel - Germany

Phone: +49 (0) 6101 603-165 E-Mail: <u>press@stada.de</u>

Or visit us on the Internet at <a href="https://www.stada.com/press">www.stada.com/press</a>

Follow <u>@STADAGroup</u> on LinkedIn

## Additional information for capital market participants:

STADA Arzneimittel AG - Investor & Creditor Relations Stadastrasse 2-18

61118 Bad Vilbel – Germany Phone: +49 (0) 6101 603-4689 Fax: +49 (0) 6101 603-215

E-mail: ir@stada.de

Or visit us on the Internet at www.stada.com/investor-relations

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler Chairman of the Supervisory Board: Dr. Günter von Au